BioCryst Pharma (BCRX) Tops Q4 EPS by 1c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.81 +0.57%
EPS Growth %: -43.8%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -43.8%
Financial Fact:
Loss from operations: -9.24M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $6.34 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- BlockchainK2 plans private placement to raise up to $130,000
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
